Amicus Therapeutics Inc. | Key People and Executives
John Francis Crowley
Chairman & Chief Executive Officer
Bradley L. Campbell
President, Chief Operating Officer & Director
Lynn Dorsey Bleil
Director
Michael G. Raab
Lead Independent Director
Craig A. Wheeler
Independent Director
Glenn P. Sblendorio
Independent Director
Donald J. Hayden
Lead Independent Director
Robert A. Essner
Independent Director
Ted W. Love
Independent Director
Margaret G. McGlynn
Independent Director
John Francis Crowley
Chairman & Chief Executive Officer
Bradley L. Campbell
President, Chief Operating Officer & Director
William D. Baird
Chief Financial Officer
Jay A. Barth
Chief Medical Officer
Hung Do
Chief Scientific Officer
Daphne E. Quimi
Senior Vice President-Finance & Administration
Jeffrey P. Castelli
Chief Portfolio Officer
Enrique Dilone
Senior Vice President-Technical Operations
Mike C. Diem
Senior VP-Business & Corporate Development
Dipal Doshi
Chief Business Officer
Jayne C. Gershkowitz
Chief Patient Advocate
Kenneth J. Valenzano
Senior Vice President-Preclinical Research
Patrik S. Florencio
Chief Compliance Officer
Willem W. van Weperen
Regional Vice President
Lynn Dorsey Bleil
Director
Mark Baldry
Vice President-Global Marketing
Samantha Prout
Chief Accounting Officer & Controller
Sara Pellegrino
Vice President-IR & Corporate Communications
Kurt J. W. Andrews
Senior Vice President-Human Resources
Ellen Stacy Rosenberg
Secretary & General Counsel
Michael G. Raab
Lead Independent Director
Craig A. Wheeler
Independent Director
Glenn P. Sblendorio
Independent Director
Donald J. Hayden
Lead Independent Director
Robert A. Essner
Independent Director
Ted W. Love
Independent Director
Margaret G. McGlynn
Independent Director
| Address |
1 Cedar Brook Drive
Cranbury New Jersey 08512
United States
|
|
Employees
|
- |
| Website |
http://www.amicusrx.com |
| Updated |
07/08/2019 |
| Amicus Therapeutics, Inc. is a biotechnology company, which is engaged in the discovery, development and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |
